{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:47:29Z","timestamp":1792723649699,"version":"4.5.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Bridging the low-density lipoprotein cholesterol (LDL-C) care gap in patients with established atherosclerotic cardiovascular disease (ASCVD) is challenging. Few quality improvement (QI) interventions have successfully improved patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of a digitally enabled, multifaceted, QI intervention on the control of LDL-C concentration in patients with ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting and Participants<\/jats:title>\n                    <jats:p>This was a pragmatic, 2-arm, cluster randomized clinical trial. A total of 28 clusters (public or private outpatient clinics) in Brazil were randomized to receive a digitally enabled QI intervention or routine practice (control). Adult patients (\u226518 years) with established ASCVD were enrolled between November 2023 and December 2024 and followed up for 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>The intervention comprised a structured, digitally enabled QI strategy integrating previsit screening, electronic clinical decision support algorithms, audit and feedback mechanisms, and targeted clinician and patient engagement tools embedded within routine workflows to support lipid monitoring, treatment intensification, and adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was mean LDL-C level at 6 months. Secondary outcomes included relative LDL-C change, achievement of LDL-C targets (&amp;amp;lt;50 mg\/dL and \u226550% reduction; to convert to millimoles per liter, multiply by 0.0259), and prescription of lipid-lowering therapies. All analyses were performed following the intention-to-treat principle and accounted for the cluster design by using a generalized estimating equations model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1465 enrolled patients (mean [SD] age, 62.3 [10.1] years; 894 male [61.0%]; 714 intervention; 751 control), mean (SD) LDL-C concentration at 6 months was 76.3 (37.5) mg\/dL in the intervention group and 85.6 (37.1) mg\/dL in the control group. The adjusted mean difference was \u22126.62 mg\/dL (95% CI, \u221211.11 to \u22122.13 mg\/dL;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.004). Patients in the intervention group were more likely to achieve an LDL-C concentration less than 50 mg\/dL (23.5% vs 13.4%; odds ratio, 1.86; 95% CI, 1.30-2.65) and a 50% or greater reduction in LDL-C concentration (18.6% vs 13.4%; odds ratio, 1.76; 95% CI, 1.27-2.43). Prescription of intensive and combination lipid-lowering therapy was significantly higher in the intervention group. No significant differences in major cardiovascular events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this pragmatic cluster randomized clinical trial, a digitally enabled, multifaceted strategy produced modest LDL-C reduction and increased treatment intensification among patients with ASCVD. However, a proportion of patients had LDL-C levels that remained above recommended LDL-C targets, underscoring that the strategy tested was only partially effective in eliminating the residual care gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05622929?id=NCT05622929&amp;amp;amp;viewType=Card&amp;amp;amp;rank=1\">NCT05622929<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.2510","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:30:34Z","timestamp":1784734234000},"page":"810","source":"Crossref","is-referenced-by-count":2,"title":["Digitally Enabled Quality Improvement Intervention and LDL-C Control in Atherosclerotic Cardiovascular Disease"],"prefix":"10.1001","volume":"11","author":[{"given":"M. Julia","family":"Machline-Carrion","sequence":"first","affiliation":[{"name":"epHealth, Saco Grande, Florian\u00f3polis, Brazil"},{"name":"Instituto epHealth, Consola\u00e7\u00e3o, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Santo","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysson Nathan","family":"Girotto","sequence":"additional","affiliation":[{"name":"epHealth, Saco Grande, Florian\u00f3polis, Brazil"},{"name":"Instituto epHealth, Consola\u00e7\u00e3o, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Raupp","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Brazil, Cidade Mon\u00e7\u00f5es, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Marton","family":"Pereira","sequence":"additional","affiliation":[{"name":"epHealth, Saco Grande, Florian\u00f3polis, Brazil"},{"name":"Instituto epHealth, Consola\u00e7\u00e3o, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico","family":"Monfardini","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Hideo","family":"Nakagawa Santos","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"Pereira","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"dos Santos Sampaio","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Moia","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"de Oliveira Farias","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico Toledo Campo","family":"Dall\u2019Orto","sequence":"additional","affiliation":[{"name":"Hospital Maternidade e Pronto Socorro Santa L\u00facia, de Caldas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pavanello","sequence":"additional","affiliation":[{"name":"Instituto Dante Pazzanese de Cardiologia, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carisi Anne","family":"Polanczyk","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odilson Marcos","family":"Silvestre","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Silvestre Sant\u00e9, Rio Branco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Heitor Vieira","family":"Assad","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cardiologia, Laranjeiras, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sanali Moura","family":"de Oliveira Paiva","sequence":"additional","affiliation":[{"name":"Instituto Atena de Pesquisa Cl\u00ednica, Natal, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayler Olombrada Nunes","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Hospital Municipal de Aparecida de Goi\u00e2nia \u2013 SBIB Hospital Albert Einstein, de Goi\u00e2nia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Politi","family":"Okoshi","sequence":"additional","affiliation":[{"name":"Unidade de Pesquisa Cl\u00ednica da Faculdade de Medicina de Botucatu \u2013 UNESP, S\/N, Distrito de Rubi\u00e3o Junior, Botucatu, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo da Costa Nunes","family":"Bosso","sequence":"additional","affiliation":[{"name":"Hospital Regional de Presidente Prudente, Presidente Prudente, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Andrade","family":"de Azeredo Bastos","sequence":"additional","affiliation":[{"name":"Hospital Ruy Azeredo, Goi\u00e2nia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"de Moura Joaquim","sequence":"additional","affiliation":[{"name":"Instituto de Cardiologia de Santa Catarina, S\/N, S\u00e3o Jos\u00e9, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Airton","family":"Arruda","sequence":"additional","affiliation":[{"name":"Associa\u00e7\u00e3o Evang\u00e9lica Beneficente Esp\u00edrito-Santense \u2013 AEBES, S\/N, Vila Velha, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Ferreira","family":"Araujo","sequence":"additional","affiliation":[{"name":"Hospital Municipal Ant\u00f4nio Giglio, Osasco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Riquena","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Brazil, Cidade Mon\u00e7\u00f5es, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Rezende","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Brazil, Cidade Mon\u00e7\u00f5es, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenio","family":"Alvarenga","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Brazil, Cidade Mon\u00e7\u00f5es, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein, Morumbi, S\u00e3o Paulo, Brazil"},{"name":"Lipid Clinic Heart Institute InCor University of S\u00e3o Paulo Medical School Hospital, Cerqueira C\u00e9sar, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ot\u00e1vio","family":"Berwanger","sequence":"additional","affiliation":[{"name":"Imperial College London, London, United Kingdom"},{"name":"The George Institute for Global Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SAPPHIRE-LDL Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9841","key":"hoi260037r2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials.","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"32","key":"hoi260037r3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease\u20141. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"24","key":"hoi260037r4","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi260037r5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"hoi260037r6","doi-asserted-by":"publisher","DOI":"10.36660\/abc.20250640","article-title":"Brazilian guideline on dyslipidemias and prevention of atherosclerosis 2025.","volume":"122","author":"Rached","year":"2025","journal-title":"Arq Bras Cardiol"},{"issue":"25","key":"hoi260037r7","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1161\/CIR.0000000000000624","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"hoi260037r8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"hoi260037r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high\u2013risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"hoi260037r10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.36660\/abc.20190885","article-title":"Avalia\u00e7\u00e3o do seguimento de 1 ano dos pacientes inclu\u00eddos no Registro da Pr\u00e1tica Cl\u00ednica em Pacientes de Alto Risco Cardiovascular (REACT).","volume":"116","author":"Silva","year":"2021","journal-title":"Arq Bras Cardiol"},{"issue":"5","key":"hoi260037r11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jamacardio.2019.0649","article-title":"Effect of a multifaceted quality improvement intervention on the prescription of evidence-based treatment in patients at high cardiovascular risk in Brazil: the BRIDGE cardiovascular prevention cluster randomized clinical trial.","volume":"4","author":"Machline-Carrion","year":"2019","journal-title":"JAMA Cardiol"},{"key":"hoi260037r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.01.019","article-title":"Rationale, design and prerandomization data for a cluster randomized trial to assess the effect of a digitally enabled quality improvement intervention on LDL-C control in established atherosclerotic cardiovascular disease patients: the SAPPHIRE-LDL trial.","volume":"284","author":"Machline-Carrion","year":"2025","journal-title":"Am Heart J"},{"issue":"9493","key":"hoi260037r13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90?056 participants in 14 randomized trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9753","key":"hoi260037r14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170?000 participants in 26 randomized trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"hoi260037r15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000259.pub3","article-title":"Audit and feedback: effects on professional practice and health care outcomes.","volume":"2012","author":"Ivers","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"hoi260037r16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US.","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"1","key":"hoi260037r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102403","article-title":"GOULD EDU: cluster-randomized trial of an educational intervention to improve lipid-lowering guideline adherence.","volume":"5","author":"Cannon","year":"2026","journal-title":"JACC Adv"},{"issue":"2","key":"hoi260037r18","doi-asserted-by":"publisher","DOI":"10.1093\/ehjdh\/ztaf135","article-title":"Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial.","volume":"7","author":"Stevens","year":"2025","journal-title":"Eur Heart J Digit Health"},{"issue":"23","key":"hoi260037r19","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1161\/CIRCULATIONAHA.124.069494","article-title":"Randomized evaluation of a remote management program to improve guideline-directed medical therapy: the DRIVE trial.","volume":"149","author":"Blood","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"hoi260037r20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.36660\/abc.20210840","article-title":"O desafio de incorporar tecnologias de alto custo: uma an\u00e1lise dos inibidores de PCSK9.","volume":"117","author":"Marcolino","year":"2021","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"hoi260037r21","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1038\/s41598-024-54516-9","article-title":"Primary results of the brazilian registry of atherothrombotic disease (NEAT).","volume":"14","author":"de Barros E Silva","year":"2024","journal-title":"Sci Rep"},{"issue":"8","key":"hoi260037r22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamaneurol.2019.1012","article-title":"Effect of a quality improvement intervention on adherence to therapies for patients with acute ischemic stroke and transient ischemic attack: a cluster randomized clinical trial.","volume":"76","author":"Machline-Carrion","year":"2019","journal-title":"JAMA Neurol"},{"issue":"19","key":"hoi260037r23","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.2012.413","article-title":"Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.","volume":"307","author":"Berwanger","year":"2012","journal-title":"JAMA"},{"issue":"36","key":"hoi260037r24","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1093\/eurheartj\/ehae471","article-title":"Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.","volume":"45","author":"Nurmohamed","year":"2024","journal-title":"Eur Heart J"},{"key":"hoi260037r1","unstructured":"de Oliveira? GMM, Brant? LCC, Polanczyk? CA, .  Cardiovascular Statistics \u2013 Brazil 2023. In Portuguese. SciELO. Published online December 14, 2023. https:\/\/preprints.scielo.org\/index.php\/scielo\/preprint\/view\/7707\/version\/8152"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2851752\/jamacardiology_machlinecarrion_2026_oi_260037_1788536062.73726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:01Z","timestamp":1788966061000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2851752"}},"subtitle":["The SAPPHIRE-LDL Cluster Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.2510","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}